<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2299">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131230</url>
  </required_header>
  <id_info>
    <org_study_id>L02HOF</org_study_id>
    <nct_id>NCT05131230</nct_id>
  </id_info>
  <brief_title>CytoSorb® in Patients With Acute on Chronic Liver Failure</brief_title>
  <acronym>HepOnFire</acronym>
  <official_title>A Prospective, Multi-Centre, Propensity Score Based Matched Pair Controlled, Study of Standard Medical Care Plus CytoSorb® 300 mL Device Compared to Standard Medical Care Alone in Patients With Acute on Chronic Liver Failure Due to Severe Alcoholic Hepatitis in Combination With Systemic Hyperinflammation and Acute on Chronic Liver Failure Score ≥2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytoSorbents Europe GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytoSorbents Europe GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety and performance of the CytoSorb® therapy&#xD;
      in patients with Acute on Chronic Liver Failure (ACLF) grade ≥ 2 due to a severe alcohol&#xD;
      induced hepatitis (Maddrey DF &gt; 32) and a severe inflammatory response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 6, 2021</start_date>
  <completion_date type="Anticipated">January 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 13, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients in each group with Acute on Chronic Liver Failure (ACLF) grade &lt;2</measure>
    <time_frame>7 Days</time_frame>
    <description>To evaluate effectiveness of the CytoSorb® treatment compared to control group by comparing the proportion of patients in each group with ACLF grade &lt;2 at the end of Day 7 after CytoSorb® therapy start (assessed by https://www.efclif.com/scientific-activity/score-calculators/clif-c-aclf).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of CytoSorb treatment</measure>
    <time_frame>30 Days</time_frame>
    <description>To evaluate if CytoSorb® treatment plus Standard Medical Care (SMC) compared to SMC alone is safe and tolerable as assessed by the incidence of SA(D)Es, ADEs, DDs, SADEs, and USADEs.&#xD;
SAE - Severe Adverse Effect; ADE - Adverse Device Effect; SADE - Severe Adverse Device Effect; DD - Device Deficiencies; USADE - Unexpected Serious Adverse Device Effect</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute on Chronic Liver Failure</condition>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>CytoSorb group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CytoSorb® treatment</intervention_name>
    <description>Patients with Acute on Chronic Liver Failure (ACLF) due to Severe Alcoholic Hepatitis in combination with systemic inflammation and ACLF grade ≥2 will be enrolled in this study. Every patient that is screened, fulfills the inclusion/exclusion criteria, and consents to the study, will be allowed to enter the study. Patients will receive Standard of Care treatment for alcoholic hepatitis plus treatment with the CytoSorb® 300 mL device.</description>
    <arm_group_label>CytoSorb group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        30 patients meeting the eligibility requirements of the study will receive Standard of Care&#xD;
        treatment for alcoholic hepatitis (including steroid therapy according to AASLD/EASL&#xD;
        guidelines and extracorporeal treatments when indicated) plus treatment with the CytoSorb®&#xD;
        300 mL device, a hemoperfusion adsorbent CE-certified therapy for the removal of bilirubin&#xD;
        and pro-inflammatory cytokines (CytoSorb group).&#xD;
&#xD;
        30 propensity score matched controls from a patient database will be drawn from existing US&#xD;
        and European sources (prospectively collected databases from geographies with comparable&#xD;
        Standard of Care). The 30 CytoSorb group patients will be compared with these database&#xD;
        patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age≥18&#xD;
&#xD;
          2. Signed Informed Consent Form (ICF)&#xD;
&#xD;
          3. Total bilirubin ≥ 8 mg/dL&#xD;
&#xD;
          4. Acute Alcoholic Hepatitis diagnosed by EtOH consumption within 6 weeks of onset of&#xD;
             symptoms, exclusion of other causes for jaundice and liver biopsy or at least 2 out of&#xD;
             the following symptoms:&#xD;
&#xD;
               -  Hepatomegaly&#xD;
&#xD;
               -  AST &gt; ALT&#xD;
&#xD;
               -  Elevated WBC&#xD;
&#xD;
               -  Ascites&#xD;
&#xD;
          5. Maddrey DF &gt; 32&#xD;
&#xD;
          6. Systemic inflammation as defined by 2 fulfilled criteria out of:&#xD;
&#xD;
               -  leucocytosis&#xD;
&#xD;
               -  body temperature &gt; 38°C&#xD;
&#xD;
               -  tachycardia &gt; 90 bpm&#xD;
&#xD;
               -  tachypnoeia &gt; 20 breaths/min&#xD;
&#xD;
          7. ACLF grade ≥2&#xD;
&#xD;
          8. Creatinine &gt;2 mg/dl and increase &gt;1.5 mg/dl despite standard of care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Platelets &lt; 40,000/mm3&#xD;
&#xD;
          2. INR &gt; 3.5&#xD;
&#xD;
          3. MELD Score &gt; 35&#xD;
&#xD;
          4. AST &gt; 500 IU/l&#xD;
&#xD;
          5. Bilirubin reduction &gt; 20% in prior 72 hours (early responders to conventional Standard&#xD;
             of Care (SOC))&#xD;
&#xD;
          6. Uncontrolled infection, bleeding or hemodynamic instability&#xD;
&#xD;
          7. Small liver size (diagnosed by imaging, ultrasound/CT)&#xD;
&#xD;
          8. Chronic dialysis&#xD;
&#xD;
          9. Contraindications for CytoSorb® according to Instructions for Use&#xD;
&#xD;
         10. ACLF grade &lt;2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sven Giersdorf, PhD</last_name>
    <phone>+49 30 65499145</phone>
    <email>clinical@cytosorbents.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Jan Stange, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jan Stange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

